• Finnish Medical Society Duodecim. Benign prostatic hyperplasia. In: EBM Guidelines. Evidence-Based Medicine [Internet]. Helsinki, Finland: Wiley Interscience. John Wiley & Sons; 2007 Apr 16 [Various].

Note: This guideline has been updated. The National Guideline Clearinghouse (NGC) is working to update this summary.

Note: This guideline has been updated. The National Guideline Clearinghouse (NGC) is working to update this summary. The recommendations that follow are based on the previous version of the guideline.

The levels of evidence [A-D] supporting the recommendations are defined at the end of the "Major Recommendations" field.

Aims

• The diagnosis of benign prostatic hyperplasia is based on symptoms and basic investigations. Other causes of voiding disturbances (prostate cancer in particular) are excluded.
• Conditions requiring surgical management are recognized.
• Follow-up alone or drug therapy are good options in patients with relatively mild symptoms and no complications of urinary tract stricture.

Symptoms

• Storage symptoms
  • Extraordinary voiding frequency
  • Nocturia
  • Urinary urgency
  • Urge incontinence
• Voiding symptoms
  • Difficulty in the initiation of voiding
  • Poor urine flow
  • Need to strain while voiding
  • Discontinued voiding
  • Feeling of inadequate bladder emptying
  • Urinary retention

Primary Investigations

• Symptom questionnaire
  • A commonly used questionnaire is International Prostatic Symptom Score (IPSS)
  • The questionnaire is useful in the assessment of severity of symptoms when decisions are made between follow-up, drug treatment, and surgery.
• Writing down details associated with voiding
• DRE (digital rectum examination)
• Urinalysis
• Serum/plasma creatinine
• Serum prostate-specific antigen (PSA)
• Residual urine volume is determined by ultrasonography (see the Finnish Medical Society Duodecim guideline "Determining the Volume of Residual Urine by Ultrasonography") (or, if ultrasonography is not available, by catheterization). Ultrasonography is useful in the determination of prostatic size (calculated with the same equation as residual urine volume [see the Finnish Medical Society Duodecim guideline "Determining the Volume of Residual Urine by Ultrasonography"]), shape, and eventual hydronephrosis.
• Differential diagnosis, see table below.

Table: Differential Diagnosis on Benign Prostatic Hyperplasia

Indications for Specialist Consultation

Indications for Diagnostic Investigations by the Urologist

• The patient is below 50 years of age.
• DRE is suspicious (nodules or induration).
• Serum PSA is above 10 micrograms/L (above 3 micrograms/L in patients below 65 years of age).
  • If the serum total PSA concentration is in the range of 3 to 10 micrograms/L, measuring free/total PSA ratio is recommended. If this value is under 0.15, the probability of prostatic cancer is increased (Walsh, 1996) and a urologist should be consulted.
  • DRE before determination of serum PSA level does not influence the result.
• Rapidly developing symptoms
• Haematuria (cystoscopy)
• Diabetics who may have neuropathy
• History of pelvic surgery or irradiation
• Neurological disease or injury affecting the function of the urinary bladder
• Necessary medication affecting the function of the urinary bladder
• Lower abdominal pain as the main symptom
• Discrepancy between symptoms and findings
• The investigations performed by the urologist usually include:
  • Urine flow measurement
  • Transrectal ultrasonography
• And if necessary also
  • Cystometry and pressure-flow examination (recommended before deciding on surgery if the peak flow is >10 mL/s and also when there is a discrepancy between symptoms and findings or the patient has undergone surgery of the lower urinary tract)
  • Urethrocystography
  • Urography
  • Prostatic biopsies
  • Cystoscopy

Surgical Treatment Is Indicated in the Following Cases

• Urinary retention, overflow incontinence, or repeatedly more than 300 mL of residual urine
• Severe symptoms not relieved by drug therapy
• Severe narrowing based on measurement of flow rate
• Dilatation of the upper urinary tract
• Impairment of renal function
• Recurrent macroscopic haematuria
• Urinary tract infections
• Bladder calculi
• Severe or moderate symptoms in a patient who wants rapid relief or if satisfactory results have not been obtained with other treatments

Conservative Treatment

Follow-up

• As the symptoms of benign prostatic hyperplasia (BPH) vary greatly and the course of the disease in an individual cannot be fully predicted, follow-up is a suitable approach in patients with mild symptoms. Also in moderate symptoms, follow-up can be the initial approach if the symptoms do not essentially affect the quality of life and complications ave not developed.
• Follow-up includes explaining to the patient the nature of the disease and carrying out basic investigations annually or when symptoms have changed. Opportunistic follow-up during other encounters in primary care is one method of screening.

Drug Treatment

• Although the effectiveness of drug treatment is not as good as that of surgery it is often sufficient for reducing or alleviating the symptoms.
• When deciding on the treatment, cost-effectiveness should also be evaluated (i.e., when would invasive therapy, which usually gives complete cure, cost less and be more convenient for the patient than drug therapy continuing for years). Transurethral resection is more cost-effective than drug treatment.
• Patients on drug treatment should be followed up regularly at 6- to 12-month intervals to detect complications resulting from urethral obstruction.
• The size of the prostate and total serum PSA determine the selection of the therapy (Boyle, Gould, & Roehrborn, 1996; Boyle et al., 2003) [C]. If the prostate is not markedly enlarged on palpation or in ultrasonography (<30 mL) and PSA is <1.5 micrograms/L, the first choice is an alpha₁-blocker (e.g., tamsulosin or alfuzosin) (Lepor et al., 1996; Boyle, Gould, & Roehrborn, 1996). If the prostate is markedly enlarged or PSA is >1.5 micrograms/L, either 5-alpha-reductase inhibitor (finasteride, dutasteride) (Wilde & Goa, 1999; Roehrborn et al., 2002; Debruyne et al., 2004) [A] or an alpha₁-blocker can be used.
• A combination of 5-alpha-reductase inhibitor and alpha₁-blocker alleviates symptoms more effectively than either drug alone (McConnell et al, 2003) [B].

Alpha-blockers

• Tamsulosin (Wilt, MacDonald, & Rutks, 2002) [A], alfuzosin, doxazosin, terazosin, and prazosin
• Alpha₁-blockers (Webber, 2005) [A] decrease symptoms, increase peak urinary flow, and reduce the volume of residual urine significantly more than placebo.
• The effect of alpha₁-blockers is seen rapidly, and it has been shown to continue for several years.
• The patients should be followed up initially at 1- to 3-month intervals.
• The side effects include dizziness, postural hypotension, and missing of ejaculation, which is more rare with alfuzosin than with tamsulosin. With selective tamsulosin and alfuzosin the risk of hypotension is lower.

5-alpha-reductase inhibitors (5ARI)

• The dose of finasteride is 5 mg x 1 and that of dutasteride is 0.5 mg x 1.
• The symptoms are alleviated, the urine flow is increased, and the obstruction is decreased (Wilde & Goa, 1999; Roehrborn et al., 2002; Debruyne et al., 2004) [A].
• The effect is at its best in patients with large prostates (Boyle, Gould, & Roehrborn, 1996; Boyle et al., 2003) [C] (Walsh, 1996).
• The effect starts slowly, sometimes as late as 6 months after the onset of treatment. If no effect is observed in 6 months the indications for surgery should be reconsidered.
• The drug decreases prostatic size but the prostate returns to its original size a few months after discontinuation of treatment.
• Impotence may occur as an adverse effect.
• Although treatment with 5-alpha-reductase inhibitors decreases serum PSA level by about 50% this makes follow-up no more difficult than with alpha-blockers: an increasing PSA concentration is an indication for investigation by a urologist.

Surgical and Other Invasive Treatments

• Transurethral resection of the prostate (TURP) (Webber, 2005) [A]
  • The only treatment for complicated prostatic hyperplasia and the best documented treatment for uncomplicated disease
  • Results very seldom in erectile dysfunction (though in most cases already before operation), almost always retrograde ejaculation.
• Transurethral incision of the prostate (TUIP)
  • Suitable for patients with prostates <30 mL in volume and with no prominent median lobe protruding towards the bladder
• Open prostatectomy
  • Rarely used nowadays (prostate >100 mL)
• Green laser treatment
  • An alternative to transurethral resection
  • Data on the outcomes in long-term follow-up are lacking.
• Thermotherapy (microwave treatment) (Webber, 2005) [A]
  • Alleviates irritative symptoms
  • Long-term results are not available
• Stent or spiral
  • Can be used in selected cases in patients with a poor general condition

Catheter

• Percutaneous cystostomy is indicated in patients with urinary retention waiting for surgery (good skills in the insertion technique required).
• In selected cases repeated catheterization can be used (preferably by the patient himself).
• A silicon catheter with the balloon filled with hypertonic (5%) saline or glyserol can be used, but percutaneous cystostomy is preferred.

Treatment after TURP

• Urine bacterial culture should be taken routinely 4 to 6 weeks after the operation to detect bacteriuria, and always if a urinary tract infection is suspected (pyuria and haematuria may occur as long as 3 months after the operation).
• If bacterial growth is detected, antibiotics are indicated.
• Stress incontinence may be alleviated within 1 year: exercises of pelvic floor muscles may help.
• Antimuscarinic drugs (oxybutynin, tolterodine, trospium chloride, solifenacin, or darifenacin) can be used for the treatment of urge incontinence and nocturia.

Related Resources

Cochrane Reviews

• Pygeum africanum may have some efficacy for benign prostatic hyperplasia (Wilt et al., 1998) [C].

Other Evidence Summaries

• Phytotherapy with Hypoxis rooperi or Secale cereale may improve symptoms of benign prostatic hyperplasia. Urtica dioica or Curcubita pepo may not be effective when used alone. Phytotherapies are well tolerated (Wilt et al., 2000) [C].
• Holmium: YAG laser appears to be an effective treatment for benign prostatic hyperplasia (Larizgoitia & Pons, 1999) [B].

Definitions:

Levels of Evidence

1. Quality of Evidence: High

   Further research is very unlikely to change confidence in the estimate of effect

   • Several high-quality studies with consistent results
   • In special cases: one large, high-quality multi-centre trial

2. Quality of Evidence: Moderate

   Further research is likely to have an important impact on confidence in the estimate of effect and may change the estimate.

   • One high-quality study
   • Several studies with some limitations

3. Quality of Evidence: Low

   Further research is very likely to have an important impact on confidence in the estimate of effect and is likely to change the estimate.

   • One or more studies with severe limitations

4. Quality of Evidence: Very Low

   Any estimate of effect is very uncertain.

   • Expert opinion
   • No direct research evidence
   • One or more studies with very severe limitations

None provided

Concise summaries of scientific evidence attached to the individual guidelines are the unique feature of the Evidence-Based Medicine Guidelines. The evidence summaries allow the clinician to judge how well-founded the treatment recommendations are. The type of supporting evidence is identified and graded for select recommendations (see the "Major Recommendations" field).

• Finnish Medical Society Duodecim. Benign prostatic hyperplasia. In: EBM Guidelines. Evidence-Based Medicine [Internet]. Helsinki, Finland: Wiley Interscience. John Wiley & Sons; 2007 Apr 16 [Various].

Not applicable: The guideline was not adapted from another source.

2001 Apr 30 (revised 2007 Apr 16)

Finnish Medical Society Duodecim - Professional Association

Finnish Medical Society Duodecim

Editorial Team of EBM Guidelines

Primary Author: Teuvo Tammela

Not stated

Note: This guideline has been updated. The National Guideline Clearinghouse (NGC) is working to update this summary.

None available

None available

This summary was completed by ECRI on August 28, 2001. The information was verified by the guideline developer as of October 26, 2001. This summary was updated by ECRI on December 9, 2002, December 29, 2003, July 15, 2004, February 18, 2005, and November 2, 2005. This summary was updated by ECRI on November 30, 2005 following the U.S. Food and Drug Administration (FDA) advisory on Flomax. This summary was updated by ECRI on December 26, 2006, and again on November 12, 2007.

This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.